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4.1
Introduction
Although microbial cells and enzymes have been used by humans for millennia
to produce a variety of foodstuffs, it was not until the twentieth century that bio-
catalysis was introduced in the chemical industry. Since that time it has grown
to become an established technology for chemical manufacturing. Examples of
biocatalytic processes currently successfully operated at industrial scale are the
production of the low-calorie sweetener aspartame (1) catalyzed by the protease
thermolysin [1, 2], the production of the bulk chemical acrylamide (2) using a
nitrile hydratase [3, 4], and the production of d-p-hydroxyphenylglycine (3) using
microbial cells containing a hydantoinase and a carbamoylase [5, 6].
The recent need for more sustainable processes has driven the implementa-
tion of biocatalysis in industry further, in many cases by replacing existing
chemical processes. An example of such second-generation “green processes” is
the chemo-enzymatic synthesis of the semi-synthetic -lactam antibiotic cepha-
lexin (6). In this new process concept the side-chain d-phenylglycine (4a), acti-
vated as amide (4b) or ester (4c), is coupled to the -lactam nucleus 7-amino-
desacetoxycephalosporanic acid (7-ADCA, 5) by a penicillin G acylase (Figure
4.1) [7]. This process fully exploits the advantages of a biocatalyst in an indus-
trial setting. The coupling reaction of activated side-chain and nucleus is done
in water at ambient temperature, thereby eliminating the use of halogenated
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solvents and low temperatures. The strict selectivity of the biocatalyst contrib-
utes to the high efficiency and increased sustainability of this chemo-enzymatic
process making protection of the two building blocks and deprotection of the
coupling product superfluous [8, 9]. Altogether, over 140 processes using en-
zymes in isolated form or microbial cells have been commercialized up to now,
most of which deliver small-scale chiral products for applications in the phar-
maceutical sector [10, 11].
Chemical custom manufacturing (CCM) is the industry segment in which the
fine chemicals industry produces a compound on demand for a client (usually a
pharmaceutical company) in a one-to-one relation (as opposed to multi-client
products). In this highly dynamic business area, speed and responsiveness are
among the most important key success factors. General timelines for CCM are
given in Table 4.1. It can be seen that proof of principle including a sample of-
ten needs to be delivered to the customer within just three months.
In CCM the use of biocatalysis for the production of (chiral) fine chemicals is
still limited compared with, for instance, resolution via diastereomer crystalliza-
tion or chromatography, asymmetric organometal catalysis, or conventional
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Fig. 4.1 Penicillin G acylase-catalyzed synthesis of the semi-synthetic
-lactam antibiotic cephalexin (6).




Chemical route exists but usually
high costs
Quest for alternatives begins
2 weeks Selection of 2–3 routes Based on rough cost price estimates
Plan and quote to customer
After customer’s positive response,
experimental work begins
2 months Feasibility demonstrated Final choice made
More accurate cost price calculated
3 months Lab sample delivered for
approval by customer
Based on specs or use tests
chemistry starting from the chiral pool [12, 13]. The main reason for this differ-
ence is the long lead time to find and implement a biocatalytic process com-
pared with a chemical process, despite the fact that biocatalysts in general show
excellent enantio-, regio- and stereoselectivity, which, in principle, often enables
the design of shorter and more cost-efficient processes.
In order to be able to implement a biocatalytic reaction step successfully in
such a product, extremely strict timelines to (bio)catalyst identification and sub-
sequent process development need to be met. Although the three months’ time-
line and approach schematized in Table 4.1 is an average scenario and devia-
tions frequently occur, it clearly demonstrates the challenge for (bio)catalysis in
CCM: the time available for (bio)catalyst identification and (small-scale) process
development is extremely short.
In this chapter we will deal with the development of enzymatic assays and ac-
tivity-based screenings from an industrial perspective. We will focus solely on
CCM, and try to describe how this specialized branch of the chemical industry
must cope with the demanding timelines for biocatalyst identification. In the
first part, a number of prerequisites for the ideal screening will be discussed,
including one of the most important ones: integral screening time. In the sec-
ond part of this chapter, these general principles will be exemplified by a num-
ber of assay/screening methods developed for DSM’s chemical custom manu-
facturing business unit DSM Pharma Chemicals (DPC).
4.2
Prerequisites for an Effective Biocatalyst Screening in Chemical Custom
Manufacturing
Identification of a biocatalyst for a certain chemical conversion requires input of
sufficiently high-quality biodiversity to start from. In the last decade tremendous
progress has been made in the generation of such biodiversity. Construction of
expression libraries directly from environmental DNA is applied in many la-
boratories as a source of diversity. Use of this so-called metagenome now en-
ables identification of interesting biocatalysts from microorganisms that could
not be cultivated in laboratories before, increasing the biodiversity dramatically
[14]. The rapidly increasing quantity of genome sequence information, together
with improved software tools to predict the function of the encoded proteins, of-
fers another source for new enzymes. This genome sequence information can
be transferred into ready-to-screen enzymatic platforms.
Directed evolution is another relatively recent approach to the creation of bio-
diversity. Numerous formats ranging from simple error-prone polymerase chain
reaction (epPCR) [15, 16] of a single gene to shuffling of large families of genes
[17, 18] and even whole genomes [19, 20] have been published in the last 10
years to access the desired sequence space. These molecular biology tools have
become quite robust, which makes the generation of sufficiently high-quality
biodiversity no longer a limiting factor in many biocatalyst identification pro-
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grams. This is also true in CCM if the inputs for the screening (for example ex-
pression libraries and enzymatic platforms) have been generated proactively to
meet the short timelines in this industrial segment.
Screening for biocatalysts has also attracted considerable attention from aca-
demia and industry in the last decade, undeniably resulting in significant pro-
gress in this field [21, 22]. Nevertheless, the development and implementation
of a new screening within the limited time available in CCM is still a significant
challenge. The following criteria are pivotal for successful screening in this de-
manding field.
Screening for Real Conversion
One of the most commonly used statements in screening is “You get what you
screen for”. In the open and patent literature, numerous artificial substrates
have been described for colorimetric or fluorometric detection of a wide range
of enzymatic activities, but use of this type of substrate bears the inherent risk
that a biocatalyst identified does not catalyze the desired reaction. This can be
caused by steric incompatibility (artificial substrates are often larger than the ac-
tual ones) or catalytic incompatibility (certain types of artificial substrates are
more active than the actual substrates). Although improved artificial substrates
have recently been reported [23], screening for the real conversions still results
in the most reliable hits. Furthermore, synthesis of the artificial substrate can
be difficult and time consuming, which will delay the outcome of the screening,
thereby making it even harder to identify the desired biocatalyst on time.
Robust and Reliable
The ideal screening is robust and reliable. It must not suffer from matrix ef-
fects, such as small differences in pH, salt concentration, and residual growth
medium. Furthermore, interexperimental differences should be small. We no-
ticed that the robustness of screening protocols sharply decreases with increas-
ing numbers of handling (e.g. centrifugation, pipetting, and filtration). There-
fore, simple screening protocols are preferred whenever possible. Altogether,
the screening method must clearly discriminate true positive clones without de-
livering a large number of false positives.
Quantitative
To be able to discriminate positive clones the applied screening protocol must
result in a clear change of measured response. However, different types of pro-
jects require different levels of accuracy. Screening a (metagenomic) library for
new biocatalysts, for example, places less strict requirements on accuracy than
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screening in a directed evolution program to improve the catalytic performance
of an enzyme. In the first example, the scenario is more or less black and white
– the few positive clones that are expected should give a signal that is suffi-
ciently different from the background signal. The exact intensity of the signal of
the positive clones is not very useful, however, since clones containing the same
gene will often have a different genetic constitution that can severely influence
the expression of the genes on the insert fragment. Therefore, an assay that de-
livers semi-quantitative results is sufficient for this type of screening. In the
case of a directed evolution project for improved enzymes the situation is differ-
ent. In this case, the enzymatic reaction is tuned so that the conversion with
the wild-type clones amounts to about 10% conversion. Consequently, these
wild-type clones will already give a (low) signal, requiring more quantitative
screening methods. The fact that all clones to be screened contain the (mutated)
gene(s) of interest in an identical genetic constitution is another reason why
quantitative screenings are advantageous in this case. As the development of
highly quantitative screenings can be time consuming, the accuracy aimed for
should be tuned to the needs of the specific application.
Sensitive
As the most reliable results are obtained by mimicking industrial conditions in
the screening reaction as far as possible, substrate concentrations are usually
high (>50 mM). Consequently, the sensitivity of the analytical method is typical-
ly not an issue. Where the substrates or products are poorly soluble in water
the situation is different, and a sensitive analytical method is required. Using
mass spectrometry (MS) positive clones can be identified starting from substrate
concentrations as low as 0.5 mM. Addition of a cosolvent enabling higher sub-
strate concentrations is another possibility, assuming that it is not interfering
with the screening.
Integral Screening Time
This is the most important factor for screenings in CCM. It can be defined as
the time needed from the start of the screening development to the generation
of the first screening results. As will have become clear from the introductory
section, only screening methods with a short integral screening time are com-
pliant with CCM timelines. At first glance, ultra-high-throughput screening
(UHTS, in this chapter defined as a screening with a throughput of >104 sam-
ples a day) formats look suitable for application within CCM as they are charac-
terized by an extremely short analysis time per sample. However, this is cer-
tainly not true in all cases, especially when the development of UHTS methods
is time consuming (Figure 4.2).
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Reader assays (both UV/Vis and fluorescence) are appropriate, in principle,
for use in UHTS. A 96-well microtiter plate can be measured in less than 30 s,
leading to a theoretical throughput of 104–105 samples a day in the case of an
end-point measurement. Unfortunately, this throughput can only be achieved
with simple screening protocols, which are only possible when the conversion
of substrate into product leads to strong changes in molar extinction coefficient
or fluorescence. As this is quite often not the case with the actual substrates
and/or products and use of artificial substrates is undesirable, derivatization of
substrates and/or products into highly absorbing or fluorescent compounds is
necessary as an additional step. These derivatization reactions not only lead to
much more complicated screening protocols and consequently longer screening
times (less throughput), but also to much longer development times as they re-
quire careful tuning of the derivatization conditions (e.g. reagent concentration,
temperature, pH, and reaction time) and solutions for matrix effects. Overall,
this will result in a relative long integral screening time (Figure 4.2a), which
makes such a screening method less attractive for applications in CCM.
Figure 4.2b shows a situation that is better suited for use in CCM. In this
case, implementation of a screening method with very short development time
and sufficient throughput (not necessarily ultra high throughput) generates the
first screening results in a shorter period of time, leading to quicker hit identifi-
cation and start of application research as well as sample preparation for the
customer. The characteristics needed (short development time and sufficient
throughput) are offered by generic assays, as for example based on nuclear
magnetic resonance (NMR) or MS. These types of assays are characterized by
the fact that they generate distinct signals for many chemical functionalities en-
abling straightforward differentiation between substrate and product of the en-
zymatic reaction to be screened. Combined with their relatively good tolerance
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Fig. 4.2 Graphical representation of the ef-
fect of a short integral screening time on the
time 1st results are generated. (a) An ultra-
high-throughput screening with a long devel-
opment time (typical for reader assays with-
out colorimetric or fluorometric model sub-
strates). (b) A generic assay that combines
a much shorter development time with
lower throughput in the actual assay (typical
for instrumental assays like flow-injection
NMR). The gray boxes represent the
development time for the assay, and the
black boxes the time needed for the actual
measurements of all samples in a screening.
to fluctuations in the matrix, these instrumental assay techniques are quite
powerful.
A different approach is the proactive development of less generic assays for
frequently requested chemical group conversions, as for example the synthesis
of amino acids or for reactions producing ammonia as a side-product. In this
case the challenge is to find reagents that are specific for these molecules and
generate a clearly distinguishable signal in the derivatization reaction. Further-
more, this derivatization reaction must not be interfered by other chemical
groups in these molecules, which will be different in each customer’s request.
In the next sections of this chapter examples will be discussed from each of
these CCM compliant screening approaches.
4.3
CCM Compliant Screening Methods Based on Optical Spectroscopy
(UV/Vis and Fluorescence)
As stated in the previous section, reader assays are characterized by a very short
measuring time per sample. However, often this does not translate into a short
integral screening time as the product formed in the screening reaction lacks a
chromophore or fluorophore and consequently needs to be chemically derivat-
ized before it can be detected in a reader with sufficient sensitivity and selectiv-
ity. In other cases the product of the screening reaction can be detected in a
reader by a coupled enzymatic assay. In such an assay an enzymatic reaction
cascade leads to the formation of a reader detectable compound (for instance
NAD+/NADH). In both approaches, the overall screening protocols are quite
laborious and their development is often time consuming.
Nevertheless, reader assays can be successfully applied within the CCM con-
text, for instance when the formation of the (side)-products results in a strong
change in molar extinction coefficient (Section 4.3.1), or when the (side)-prod-
ucts formed belong to a category of compounds for which a derivatization meth-
od or a coupled enzymatic assay has been developed beforehand (Section 4.3.2).
4.3.1
Optical Spectroscopic Methods Based on the Spectral Properties
of the Product Itself
The possibility of implementing screening methods based solely on changes in
spectral properties upon conversion of substrate into product is small. Neverthe-
less, the great potential of this method justifies the efforts that are needed to in-
vestigate whether it is possible. Screening requests for transformations of mole-
cules that contain a suitable chromophoric or fluorophoric group can best be
started by recording the optical (UV/Vis/fluorescence) spectra of substrate and
product. In this way it can be established whether the product absorbs and/or
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emits light of a specific wavelength. By including the appropriate blanks in
these first experiments, interference of other compounds in the matrix (e.g. the
reaction buffer and cell-derived compounds) can be assessed. If these experi-
ments have a positive outcome, a simple screening procedure can be developed
in a few days.
4.3.1.1 Example: Isolation of the D-p-Hydroxyphenylglycine Aminotransferase
Gene [24]
One of the process concepts for the production of enantiomerically pure -H--
amino acids is the conversion of -keto acids to the desired amino acids by ami-
notransferases [25, 26]. For the production of the d-enantiomers of -H--amino
acids, the “standard” aminotransferases require equimolar amounts of d-Ala,
d-Glu, or d-Asp as amino donor, which makes this process less attractive as
these compounds are rather expensive. A more attractive aminotransferase pro-
cess to enantiomerically pure d--H--amino acids is possible with an enzyme
that can use cheaply available l-Glu (8) and/or l-Asp as amino donor instead of
their d-congeners. Such a stereoinverting aminotransferase had been described
before in relation to the production of d-p-hydroxyphenylglycine (3) and d-phe-
nylglycine (4a, Figure 4.1) [27, 28]. These amino acids are produced as side-
chains in the manufacture of semi-synthetic -lactam antibiotics such as cepha-
lexin (6), cephadroxyl (10), ampicillin (11), and amoxycillin (12) [9, 29]. The
reaction catalyzed by this aminotransferase (HpgAT) is shown in Figure 4.3.
We decided to identify the HpgAT gene by screening bacterial expression li-
braries including that of Pseudomonas putida NCIMB 12565, which had been re-
ported to contain HpgAT activity [27]. In this case neither a PCR-based approach
nor the synthesis of the complete gene were possible, as the sequence of the
HpgAT gene had not been published. Recording of the optical spectra of d-p-hy-
droxyphenylglycine (3) and p-hydroxyphenylglyoxylate (9) showed that the latter
compound has a specific absorbance at about 300–350 nm (Figure 4.4).
Based on this observation, we designed the following simple screening strat-
egy.
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Procedure 4.1: UV Screening of Aminotransferase Reactions
Colonies from a gene library were cultivated in microtiter plates containing
150 L of a rich medium containing the appropriate antibiotic. After 16–
20 h at 28 C, cells were harvested by centrifugation, washed once with
50 mM potassium phosphate buffer, pH 7.0, and resuspended in 180 L re-
action mix (100 mM potassium phosphate, pH 7.0, 15 mM -ketoglutarate
(7), 0.1 mM pyridoxal-phosphate (PLP) and 0.5% v/v Triton X-100. The
screening reaction was started by addition of d-p-hydroxyphenylglycine (3)
to a final concentration of 5 mM, after which the A340nm in each well was
monitored for 20 min using an Optimax microtiter plate reader (Molecular
Devices, Sunnyvale, CA, USA).
As expected, clones containing the desired HpgAT gene showed signifi-
cant increase in A340nm relative to negative wells, as can be seen in Figure
4.5. Integral screening time in this specific case was less than one month
due to the very short development time and modest analysis time (20 min-
utes per 96-well microtiter plate).
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Fig. 4.3 Reaction catalyzed by the stereoinverting D-p-hydroxyphenylglycine
aminotransferase (HpgAT) from P. putida NCIMB 12565.
Fig. 4.4 Optical spectra of p-hydroxyphenylglycine (HPG, dashed line) and
p-hydroxyphenylglyoxylate (HPGL, black line) in 45 mM potassium
phosphate buffer, pH 7.0. Concentration of both compounds was 55 M.
4.3.2
Optical Spectroscopic Methods Based on Follow-up Conversion of Product
As the majority of the industrially relevant conversions are not accompanied by
clear changes in optical signal, direct reader-based assays are frequently not an
option. In many cases, however, a reader assay can still be developed by linking
the actual screening reaction to a subsequent conversion that leads to a signal-
generating compound. This can be realized in various ways. In a first approach,
a chemical reagent or complexing agent reacts with a functional group of the
(side)-products. As these derivatization reactions often require harsher condi-
tions (especially pH) than the enzyme reaction to be screened, these types of as-
says are typically end-point measurements. Interference of the measurement by
other compounds that contain the same functional group as the product is the
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Fig. 4.5 Typical progress curves of (a) a negative E. coli clone and
(b) an E. coli clone containing the HpgAT gene from
P. putida ATCC NCIMB 12565.
major complicating factor in these derivatization-based reader assays. A second
approach is based on the subsequent conversion of one of the (side)-products of
the screening reaction in an enzymatic reaction cascade, in which the final step
is a conversion of a reader-detectable compound (for instance NAD+/NADH).
The major advantage of this second approach is the higher selectivity of the en-
zyme compared with the chemical derivatization reagent, thereby strongly re-
ducing the number of potentially interfering compounds. Furthermore, the mild
conditions needed for the enzymatic cascade more often enable measurements
in a kinetic mode.
Although possible in principle, the long development time of these kinds of
optical spectroscopic assays hampers their application in CCM. This is due to
the large number of parameters that have to be optimized and tuned, such as
concentration of the reactants and conditions (pH, temperature, and reaction
time) of the different steps as well as their order. Proactive development of ro-
bust reader assays for a number of frequently encountered types of molecules
(“group assays”) can solve this problem and makes these potentially attractive
assays CCM timelines compliant.
This approach is further elaborated in the following examples relating to syn-
thetic routes for enantiomerically pure amino acids, which are important chemi-
cal building blocks for the pharmaceutical and agrochemical industry [30].
A significant number of the CCM market requests fall within this category.
A large number of different chemo-enzymatic process concepts for the produc-
tion of enantiomerically pure amino acids (Figure 4.6) have been developed and
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Fig. 4.6 Schematic overview of different enzymatic reactions to enantio-
merically pure amino acids. (A) carbamoylase; (B) amino acid dehydro-
genase; (C) amino acid oxidase; (D) amidase; (E) nitrilase; (F) nitrile
hydratase; (G) ammonia lyase.
commercialized [31], and ammonia is involved in the majority of these concepts
either as side-product (amidases, carbamoylases, nitrilases, or amino acid oxi-
dases) or as substrate (for instance when using amino acid dehydrogenases and
ammonia lyases). We set out to develop reader assays for amino acids as well as
for ammonia and primarily focused on amidases as these are excellent tools for
the production of enantiopure -H- and ,-disubstituted -amino acids [30].
During development of the assays for ammonia, we noticed consistently high
backgrounds when crude extracts or cell suspensions of microorganisms were
used. This is caused by the growth media, which often contain yeast extract and
peptone. Growth of microorganisms in these media involves the production of
ammonia from the peptides and amino acids, as these media contain a surplus
of nitrogen over carbon. Therefore, it may be necessary to harvest the cells by
centrifugation followed by washing with a suitable buffer before starting the ac-
tual screening in order to get a sufficiently low background.
4.3.2.1 Example: Fluorometric Detection of Amidase Activity
by o-Phthaldehyde/Sulfite Derivatization of Ammonia
One of the reader assays we developed for the quantitative determination of am-
monia is based on the derivatization reaction of ammonia with o-phthalaldehyde
(15) and sulfite, which results in a fluorescent derivatization product (Figure
4.7). The exact structure of this fluorescent product is not known.
We modified the original flow-injection method [32] into an analytical proce-
dure that can be run in an automated pipetting robot in combination with a mi-
crotiter plate fluorescence reader instrument. Using this hardware combination
large numbers of enzymatic samples can be screened. The method shows con-
siderable selectivity for ammonia over amino acids and amino acid amides,
which makes the method also suitable for monitoring conversion in amidase re-
actions.
The o-phthalaldehyde/sulfite assay was successfully applied in the screening
of an epPCR mutant library of a bacterial amidase gene. This screening targeted
mutants with improved activity towards a specific -H--amino acid amide (13,
Figure 4.6), without affecting this biocat’s absolute enantioselectivity and good
process stability.
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Fig. 4.7 o-Phthalaldehyde/sulfite derivatization reaction of ammonia leading
to a fluorescent product.
Procedure 4.2: Amidase Assay by Spectroscopic Ammonia Detection
E. coli colonies containing the mutant library were cultivated in 96-wells mi-
crotiter plates containing 150 L of a rich medium supplemented with the
appropriate antibiotic and inducer. After 18 h at 37 C, 50 L cell suspension
was mixed with 50 L of a 20% racemic -H--amino acid amide solution
(pH 8). After 2 h of incubation at 55 C, the reaction was stopped by adding
200 L 1 M H3PO4, after which the microtiter plates were stored at 4 C be-
fore ammonia was assayed. The stopped assay mixture and calibration solu-
tions (vide infra) were diluted by mixing 20 L with 250 L 0.1 M H3BO3,
pH 9.5. From this mixture, 10 L was mixed with 45 L of a 50 mM o-
phthalaldehyde solution (in 25% methanol, 75% 0.53 M H3BO3, pH 9.5)
and 45 L 50 mM Na2SO3 in a 384-well microtiter plate. After 30 min at
55 C, fluorescence was determined (excitation at 390 nm, emission at
538 nm) in a Fluorstar fluorimeter (BMG laboratories GmbH, Offenburg,
Germany). As the signal obtained after this incubation at 55 C still slightly
increased in time, it was essential to measure all plates after the same deri-
vatization time.
For quantification it is a prerequisite that the calibration samples resem-
ble the gene library samples as much as possible. We achieve this by imitat-
ing a realistic amidase reaction in the same biological matrix as present in
the screened library samples (that is, as conversion proceeds we get increas-
ing amino acid and ammonia concentrations and correspondingly equimo-
lar decreasing amino acid amide concentrations). We call this a comple-
mentary calibration procedure. All calibration samples were prepared in
0.67 M H3PO4 and subjected to the same procedure as the mutant library
samples.
To establish the standard deviation of this screening method, the whole
screening protocol was executed with a few microtiter plates with E. coli
cells containing the wild-type amidase gene. The standard deviation of the
enzyme activity was less than 15%.
In this specific screening, 30 microtiter plates each containing 96 differ-
ent random clones resulted in a dataset from 2880 enzyme assays. The ab-
solute data values (Figure 4.8) were corrected for the amount of cells in the
assay by dividing the fluorescence by the optical density (OD600nm) of the
cultures.
The resulting specific activities were compared with the activity of the
wild-type clones, which resulted in the identification of 41 possible hits for
further testing. These mutants were rescreened on a somewhat larger scale.
In this second round eight positive mutants were confirmed. Chiral high-
performance liquid chromatography (HPLC) analysis of the mutants proved
that the enantioselectivity of the amidase was not lost in the mutants.
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4.3.2.2 Example: Colorimetric Detection of Amidase Activity by Detection
of Ammonia via Glutamate Dehydrogenase-coupled Assay [33]
A second reader assay we developed to measure the ammonia concentration in
high-throughput mode is based on the enzymatic oxidation of NADH by gluta-
mate dehydrogenase (EC 1.4.1.3) [34]. In this reaction glutamate dehydrogenase
converts its substrates, -ketoglutarate (7) and ammonia, into l-Glu (8) thereby
oxidizing NAD(P)H to NAD(P)+ (see Figure 4.9). The oxidation of NAD(P)H
can be followed in a spectrophotometer at 340 nm or in a fluorimeter (excitation
at 339 nm, emission at 460 nm). If the concentration of ammonia to be deter-
mined is lower than the concentration of -ketoglutarate and NAD(P)H, the de-
crease in NAD(P)H is directly related to the concentration of ammonia in the
sample. It can be calculated using the extinction coefficient of NAD(P)H at
340 nm, 6.22103 M–1cm–1.
As glutamate dehydrogenase is very specific for ammonia, high concentra-
tions of amino acids and amino acid amides do not interfere with the measure-
ments. This makes this assay very suitable for the quantification of ammonia in
samples from different enzymatic conversions as depicted in Figure 4.6, as long
as neither NAD(P)+ nor the reduced form are cofactors in such reactions. An-
other advantage of this method is the stable signal obtained after the glutamate
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Fig. 4.8 Data of an o-phthalaldehyde/sulfite screening: activities of
2880 clones from an amidase epPCR library normalized for the cell
density of the cultures (OD600nm). Wild-type level is shown as a
dashed line.
Fig. 4.9 The glutamate dehydrogenase (GDH) reaction, coupling the
amount of ammonia in a sample to oxidation of NAD(P)H.
dehydrogenase reaction has gone to completion. This makes the glutamate de-
hydrogenase incubation step less vulnerable than the o-phthaldehyde (15)/sulfite
derivatization method described in Section 4.3.2.1. Since screening projects for
biocatalysts are usually carried out with crude extracts or cell suspensions of mi-
croorganisms, these suspensions may contain high NADH oxidase activity. This
will lead to an overestimation of the ammonia concentration because NADH is
also oxidized by these enzymes. To prevent this, NADH oxidase activity (as well
as other disturbing enzyme activities that may be present in this ammonia as-
say), can be inactivated by acid treatment of cells, debris and/or proteins, fol-
lowed by removal of the precipitate via centrifugation, before assaying the am-
monia concentration. In many cases, this inactivation will not require an addi-
tional pipetting step as the addition of the acid also stops the actual screening
reaction, which is a step in many screening protocols (especially for improved
enzyme variants) anyhow. Furthermore, this acid treatment will remove all par-
ticulates from the screening reaction mixture, preventing noise in the spectro-
photometric assay.
We used the glutamate dehydrogenase ammonia assay in a screening project to
identify amino acid amide racemases (ARs) [33]. In conjunction with an enan-
tioselective amidase, these enzymes enable the synthesis of enantiomerically pure
-H--amino acids (14) from the corresponding racemic -H--amino acid amides
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Fig. 4.10 Dynamic kinetic resolution (DKR) of -H--amino acid amides
by combining an enantioselective amidase with an amino acid amide
racemase (AR), leading to 100% theoretical yield of the desired amino
acid enantiomer. The AR reaction is boxed.
(13) in a dynamic kinetic resolution (DKR) with 100% theoretical yield (Figure
4.10). Without ARs this amidase process is a kinetic resolution with an inherent
maximum yield of the desired amino acid stereoisomer of only 50%.
The method for this screening for ARs is shown in Figure 4.11. Expression li-
braries in E. coli are incubated with a d--H--amino acid amide (d-13) as sub-
strate, which is converted into the corresponding l--H--amino acid amide (l-
13) by AR-positive E. coli clones only. As the assay mixture also contains the strictly
selective l-aminopeptidase from Pseudomonas putida ATCC 12633 [30, 35], the l--
H--amino acid amide formed is hydrolyzed to the l--H--amino acid (l-14) un-
der formation of ammonia, which will subsequently be determined using the glu-
tamate dehydrogenase assay. As can be seen in Figure 4.11, this screening
approach will not only identify AR-positive clones, but also d-selective or nonselec-
tive amidase-containing clones, since they will directly hydrolyze the d--H--ami-
no acid amide screening substrate. Therefore, more specific follow-up assays were
needed to distinguish d-amidase from AR-positive clones. This was done on an
HPLC system in which all four components of the reaction mixture, namely the
-H--amino acid amide (13) and -H--amino acid (14) enantiomers, were quan-
tified after derivatization with o-phthaldehyde (15) in combination with d-3-mer-
capto-2-methylpropionic acid (16) as chiral reagent [36].
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Fig. 4.11 Schematic representation of possi-
ble reaction pathways using a D--H--amino
acid amide as screening substrate for an
amino acid amide racemase (AR). Besides
the desired pathway via the AR and L-ami-
dase, hits identified may alternatively contain
a D-amidase, potentially together with an
amino acid racemase. Both pathways lead to
formation of equimolar amounts of L--H--
amino acid and ammonia, which is subse-
quently detected using the glutamate dehy-
drogenase assay after the screening reaction
has been stopped with phosphoric acid.
Procedure 4.3: Enzyme-coupled Assay for Amino Acid Amide Racemase
via NADH Detection
The actual AR screening was executed as follows. Bacterial expression li-
braries in E. coli were cultivated in 96-well microtiter plates containing
200 L of a rich medium with the appropriate antibiotic. The cultures were
grown at 700 rpm and 28–30 C for 2 days, before cells were harvested by cen-
trifugation (10 min at 1500g), washed twice with 50 mM Tris–HCl buffer,
pH 7.5, and resuspended in 50 L of 50 mM Tris–HCl buffer, pH 7.5. The
screening reaction was started by the addition of 50 L of substrate solution
containing a mixture of 140 mM d-valine amide (d-13a), d-leucine amide
(d-13b) and d-phenylalanine amide (d-13c) each in 50 mM Tris–HCl buffer,
pH 7.5 and 2 mM MnCl2. After 20 h incubation in a microtiter plate shaker
at 30 C and 700 rpm, 2 L of help solution containing the l-aminopeptidase
from P. putida ATCC 12633 [30, 33] was added to be sure that all l--H--ami-
no acid amide (l-13) formed in the screening reaction and not yet converted
by the endogenous E. coli aminopeptidase, was converted into ammonia and
l--H--amino acid (l-14). After an additional 1.5 h incubation at 30 C, all re-
actions were stopped by the addition of 100 L of 0.15 M HCl. After removal
of the cell debris by centrifugation (10 min at 1500 g), 7 L of the clear super-
natant was transferred to new microtiter plates containing 93 L of glutamate
dehydrogenase (GDH) reagent per well. This GDH reagent contained (per
100 mL) 43 mg of NADH, 116 mg of -ketoglutarate (7), 11.8 mg of ADP
and 1200 U of GDH (Sigma, St. Louis, MO, USA) in 150 mM Tris–HCl buffer,
pH 8.0. After 15 min incubation at 37 C, potential positive clones were deter-
mined by measuring the A340nm in each well using a Spectramax 250 plus
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Fig. 4.12 Data of a glutamate dehydrogenase screening: decrease of
A340nm of 11000 clones from a gene library of O. anthropi expressed in
E. coli. Absolute values obtained have been normalized to the median
of each microtiter plate.
microtiter plate reader (Molecular Devices, Sunnyvale, CA, USA). The A340nm
values obtained in the AR screening of the Ochrobactrum anthropi IA gene li-
brary are shown in Figure 4.12.
In order to reduce plate-to-plate variation within the A340nm data, the fol-
lowing calculation method was used to identify positive hits. From each 96
data points from a 96-well microtiter plate the average A340nm and standard
deviation were calculated.
Subsequently, the standard deviation was multiplied by a factor of 3 and
subtracted from the average. The resulting number was considered as the
cut-off value. Clones with an A340nm lower than this cut-off value were
regarded as potentially positives and selected for further screening. In this
way the effect of random noise and plate-to-plate variation was diminished.
Based on this criterion, 32 potential positive clones were selected out of
the 11272 clones screened. In the follow-up assays, 22 of the 32 potential
positives showed clear -H--amino acid formation, one of which contained
the desired AR gene, as this clone clearly showed l-leucine (l-14b) forma-
tion from d-leucine amide (d-13b). The other 21 clones expressed no AR
but were most likely either d-selective or nonselective amidases.
4.3.2.3 Example: Colorimetric Detection of Amino Amidase Activity
Using Cu2+ as Sensor for Amino Acids [37]
Besides assays based on ammonia detection, we also developed reader assays
for the detection of reactions involving amino acids. One of the requirements
for such an assay was that it had to be applicable in screening of amino ami-
dases (amidases requiring an -amino group for activity). This implied that for-
mation of a small amount of -amino acid (product) in a matrix with a usually
much higher concentration of -amino acid amide (substrate) had to result in a
clearly detectable change of spectral or fluorescent properties, in spite of the fact
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Fig. 4.13 Influence of pH on max of the Cu
2+ complex of valine amide
(triangles) and valine (diamonds).
that both compounds contain a primary amine group. Furthermore, interfer-
ence of the assay by ammonia, which is formed as side-product in equimolar
amounts, had to be excluded.
Recently we described a method for the determination of amino amidase ac-
tivity that meets these requirements [37]. This method is based on the use of
Cu2+ alone as metal sensor, which distinguishes this method from earlier meth-
ods that use Cu2+ or Ni2+ as metal sensors in conjunction with a fluorescent
macrocyclic metal chelator [38, 39]. It appears that the copper complexes of an
-amino acid and an -amino acid amide have different spectral properties at al-
kaline pH (Figure 4.13).
Below pH 8, -amino acid amides form bidentate complexes with Cu2+,
wherein two Cu-O and two Cu-N bonds are present, resulting in a blue complex
(max 620–680 nm). At a pH higher than 8, a violet-red complex is formed (max
510 nm). The structures of both complexes (the blue as well as the violet-red
one) have been described before [40]. The Cu2+ complex of -amino acids, on
the other hand, stays blue upon a pH change from 3.3 to 10.8, although there
is a shift in max from 690 to 620 nm [37]. The above observations were the ba-
sis for the newly developed amino amidase assay method, as this activity will
then be indicated by a color change from violet-red (-amino acid amide) to blue
(-amino acid) provided that the pH of the color assay mixture is higher than 8
(Figure 4.14).
We successfully applied this assay method in monitoring amino amidase ac-
tivity in a large number of fractions resulting from enzyme purification studies.
-Methylvaline amide (17a) was used as substrate, which was converted into -
methylvaline (18a) by the desired amino amidase (Figure 4.15).
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Fig. 4.14 Colors of complementary calibra-
tion solutions of -methylvaline amide and
-methylvaline after complexation with Cu2+.
Color changes from violet-red (outside left
well containing 43 mM -methylvaline
amide) to blue (outside right well containing
43 mM -methylvaline and 43 mM ammo-
nia). From left to right, wells contain an in-
creasing concentration of -methylvaline and
ammonia (4.3 mM per well), and an equi-
molar decreasing concentration of -methyl-
valine amide.
(Reprinted from Analytical Biochemistry,
Vol. 330, A.L. L. Duchateau, M.G. Hillemans-
Crombach, A. van Duijnhoven, R. Reiss,
T. Sonke, A colorimetric method for
determination of amino amidase activity,
pp. 362–364, Copyright (2004), with
permission from Elsevier).
Procedure 4.4: Colorimetric Amino Amidase Assay Using Cu2+
An aliquot of 50 L of each fraction was mixed with 100 L of a 130 mM
dl--methylvaline amide solution, pH 8.0, and 50 L 400 mM HEPES-
KOH, pH 8.0 buffer. After 1 h incubation at 37 C, the amino amidase reac-
tion was stopped by the addition of 100 L 1 M H2SO4. After removal of
particulates by centrifugation, 70 L of the clear stopped reaction samples
were added to 74 L of an aqueous 20 mM CuSO4 solution followed by the
addition of 56 L of a 43 :5 mixture of 0.4 M borate buffer pH 9.4 and 10 M
KOH. After mixing for 10 s, the absorbance was determined at 620 nm in
an Optimax microtiter plate reader (Molecular Devices).
Quantification of the -methylvaline formed was possible using a comple-
mentary calibration curve approach (Section 4.3.2.1). In this specific case
such curve was prepared by mixing increasing amounts of a solution con-
taining 130 mM ammonia and 130 mM -methylvaline with correspond-
ingly decreasing amounts of a 130 mM -methylvaline amide solution (total
concentration amino acid and amino acid amide: 130 mM). Just before
measurement, 220 L of each calibration solution was mixed with 220 L
1 M H2SO4 and 220 L 0.2 M HEPES-KOH, pH 9.0 to obtain the identical
matrix as in the stopped reaction mixtures.
The results obtained showed that fractions containing the desired amino
amidase were easily distinguishable by this simple spectrophotometric as-
say. Furthermore, validation of this Cu2+ method by measuring the amino
amidase-catalyzed conversion of -methylvaline amide by this method and
HPLC/MS showed that the reader assay delivers quantitative data [37].
4.4
CCM Compliant Screening Methods Based on Generic Instrumental Assays
The short integral screening time required in CCM can also be met by use of
generic assays. These assays, which are mostly instrumental, combine extremely
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Fig. 4.15 Conversion of DL-,-disubstituted -amino acid amides by an L-amidase.
broad applicability with short development time. Therefore, the introduction of
these methods can in most cases be done reactively after receiving a question
from a customer. This clearly distinguishes them from assay methods requiring
proactive development to be compliant with CCM timelines, as is the case with
reader assays in which chemical derivatization or enzymatic cascade reactions
(Section 4.3.2) are needed to visualize the product. Generic instrumental assays,
for instance, are based on NMR and MS
4.4.1
Flow-injection NMR as Analytical Tool in High-throughput Screening
for Enzymatic Activity
NMR spectroscopy is a well-established analytical technique that can yield struc-
tural and quantitative information about molecules present in solution. Origi-
nally, it was mainly applied in the synthetic field and for physicochemical re-
search; nowadays there are numerous new applications in biology and medi-
cine. The historical drawbacks of low sensitivity and overlapping signals have
been overcome by the use of higher field strengths with their intrinsically high-
er sensitivity and better dispersion of resonances. Recently, the advent of so-
called cryo-probeheads again increased the sensitivity by a factor of four.
Minimal sample pretreatment and better capability of water suppression also
make samples of biological origin amenable for routine analysis. In enzymatic
conversions substrate and product are usually different chemical entities with
different magnetic properties, so they yield different NMR spectra. Due to the
quantitative nature of NMR spectroscopy, conversions can easily be monitored,
measuring both substrate and product.
The availability of classical sample changers makes recording of about 100
spectra per day possible. To increase the number of measurements per day, dif-
ferent methods of sample introduction have been developed and the application
of flow-through probes has increased the number by one order of magnitude,
so that 1H-NMR spectroscopy can now be applied to medium/high-throughput
screening. In the literature, screening in drug discovery and development, com-
binatorial chemistry libraries and body fluids is well described [41–45].
4.4.1.1 History
Convinced by the potential of NMR spectroscopy in the analysis of large series
of similar samples, until then limited in our practice to 60 per night, we were
thinking about increasing the throughput by alternative sample introduction
techniques. Liquid Chromatography/NMR (LC/NMR) had been developed in
the late 1980s and further developed in the 1990s and the use of sample loops
made it possible to store HPLC fractions in those loops and later introduce and
measure stored fractions in a flow-through probe. In 1995 we carried out a first
trial at the Bruker site with biological samples, manually introduced into the
sample loops. Using the software developed for LC/NMR, it turned out to be
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possible to measure those samples sequentially. Although the speed at that time
was still limited due to practical problems of the equipment (thin capillaries re-
stricting the flow), the test was successful in that it proved to be possible to
automatically introduce and measure NMR spectra of samples for which the
only treatment had been the addition of some D2O as a lock solvent [46].
Bruker biospin continued the development, supported by our real-life samples
and suggestions. They published together with the Nicholson group in open lit-
erature about the principle in 1997 and soon thereafter commercialized their
product (Bruker Efficient Sample Transport (BEST) NMR) using a Gilson 215
as a liquid handler and sample changer for vials and well plates [47].
Our first flow-through system (500 MHz) in 1998 was able to change and
measure a sample in 3.5 min, which meant a total of 400 samples per day, al-
ready 4 times more than the classical sample changers could deliver. Further
improvement, by optimizing each step in the process, turned out to be possible
in the years thereafter to about 1 min per sample. A crucial element in this was
the use of a heatable transfer capillary, which, after careful calibration, made it
possible to get the sample to the desired temperature before introduction to the
flow-cell, so that the normal temperature equilibration of 4–5 min could be
skipped and the measurement started immediately.
For a more detailed description of the principles of flow-through systems on
the market the reader is referred to the review of Stockman et al. [45]. A sche-
matic overview of the BEST NMR set-up based on the Gilson XL215 autosam-
pler is given in Figure 4.16.
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Fig. 4.16 Schematic overview of the BEST NMR system based on the
Gilson XL215 autosampler.
4.4.1.2 Current Practice
There are several reasons why NMR, and in particular flow-injection NMR, is
suitable for screening large libraries for new or improved biocatalysts. These are
explained below.
Direct Measurement of Both Substrate and Product
No artificial substrates are needed for detection purposes. As indicated earlier,
this prevents erroneous conclusions, as the artificial substrate is not representa-
tive of the aimed substrate, especially in studies to improve the catalytic proper-
ties of a specific enzyme. Derivatization reactions are also unnecessary, thus ob-
viating the need for additional steps to the screening.
Intrinsically Quantitative
Substrate and product in most cases have similar NMR properties, such as re-
laxation behavior, as long as the size of the molecule does not change dramati-
cally. As a consequence the response factor, which is unity under controlled con-
ditions, also applies under screening conditions.
Short Development Time
Finding out whether a particular (enzymatic) conversion can be detected by
NMR is easily done by measuring the spectra of the intended substrate and
product under the expected conversion conditions. This will take less than 1 h.
If successful, the actual screening can start, if not, conditions like pH or tem-
perature can be changed to see if the desired separation of the resonances can
be obtained. In general it is not necessary to separate all the resonances of the
substrate and the product, since one is sufficient.
Where no product is available yet, simulation of the NMR spectrum by specif-
ic computer programs gives an indication whether the screening in principle
would be successful. In those screenings, manual inspection of the individual
spectra is needed to find actual positive hits. This is easily done by scrolling
through the spectra at the expected region of interest.
No Calibration Necessary
Because substrate and product generally have similar molecular weights, integrals
of substrate and product resonances can be compared more or less quantitatively,
without applying the normally needed long relaxation delay (about 30 s between
scans). This way, the actual measuring time can be limited and in practice can
be made the same as the time needed for the preparation of the next sample.
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No Critical Sample Pretreatment
The standard sample pretreatment is centrifugation, sampling the supernatant with
a robotized system (e.g. 350 L) into a deep-well plate, and adding a constant
amount (50 L) of a solution containing D2O, EDTA (50 mM), and a known amount
ofmaleic acid. In this way, a lock signal is supplied, and themetal ions, present from
the cell-free extracts, are chelated to prevent broadening of the resonances. More-
over, addition of this solution supplies an internal standard to monitor unexpected
disappearance of the substrate. In the case of screening for new biocatalysts, it is
generally not necessary to stop the screening reaction, for any positive hit is wel-
come, irrespective of the response in a specific incubation time.When the screening
has been set up to improve the enzyme, the reaction should be stopped, for example
by adding acid or base, at a moment that the reaction of the wild-type enzyme is
around 10% of conversion. In that case improvements can easily be detected.
Relatively Matrix-independent
NMR spectra are in general not very sensitive to small changes in sample con-
ditions. Most substrate incubations are done between pH 5 and 7, where the in-
fluence of pH on the NMR spectrum is normally negligible. If the reaction is
stopped by the addition of acid or base, care must be taken that the resulting
pH is far enough from the pKa values of the ionizable groups in the molecule,
that is below pH 1 or above pH 12.
No Reference Material Necessary
To observe the conversion of a substrate to an expected product, it is best to
have a sample of the product available. If this is not possible, as pointed out un-
der “short development time”, the spectra have to be inspected visually to find
the resonances of the product. Once a positive hit has been found, the reso-
nance positions of the product are known and the remainder of the spectra can
be evaluated automatically.
Screening for Multiple Substrates/Products Possible
With flow-injection NMR it is possible to screen more than one substrate to be
converted at a time. The boundary condition for this is that each substrate and
product has at least one signal that does not overlap with the others, so that
conversions for each substrate can be calculated. By measuring the individual
spectra from potential substrates, clever combinations can be chosen. In our
practice, up to four different substrates have been analyzed for conversion in
one round of screening, saving time and effort needed for both the substrate in-
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cubation and the measurement. The template for the calculation of the conver-
sions can easily be adapted to report the conversions for individual substrates.
Unexpected Conversions Detectable
Another advantage of NMR spectroscopy is that, being a heuristic technique par
excellence, it is not only the expected conversion that can be measured, but also
conversions that were not intended. These can be conversions of other func-
tional groups present or follow-up reactions of primary products.
Robust
NMR spectroscopy in general is a technique without direct interaction between
the sample and the instrument during the measurement. There is no wear and
no direct contact between the sample and measuring device. In practice, there-
fore, the downtime is very low. As long as the cryogenic liquids are replenished,
the instrument will be in operation. If an electronic device fails, replacement
with that item from the manufacturer’s stock will solve the problem. For the
flow-injection NMR system a specific area that can be problematic is the flow
through the capillaries and the flow-cell. As the inlet capillary is thinnest
(0.5 mm diameter), possible clogging occurs either there or in the injection
port. In those cases, reversal of the flow and flushing with sufficient amounts
of cleaning liquid will help. Taking care that centrifugation of the microtiter
plates is done correctly and the injection needle is adjusted correctly (so that
the needle does not touch the debris present) will in practice prevent clogging.
4.4.1.3 Practical Aspects
To operate the flow-through system routinely, a number of issues need to be
dealt with.
Temperature Equilibration
As most enzyme assays are water-based, a number of spectroscopic problems
associated with NMR measurements in water (i.e. temperature equilibration
and suppression of the huge water resonance) have to be solved. The tempera-
ture of NMR probes is normally actively stabilized at a few degrees above room
temperature. As a consequence, a new sample from the sample changer has to
equilibrate from room temperature to the temperature of the probehead. This
takes about 4–5 min. By preheating the sample on the fly before entering the
flow-cell, this time can be saved, thus increasing the number of samples mea-
sured. This preheating is done in the capillary between the liquid handler and
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the probehead. Bruker developed a heatable transfer capillary that, after careful
calibration, does the job. This calibration must be done with actual samples and
using the intended dispensing speed on the fly of a series of measurements.
When the calibration is correct, the sample will be at the desired temperature
and the measurement can start immediately after sample introduction.
Adjustment of Field Homogeneity
In contrast to classical NMR tubes, the flow-cell has a constant volume and wall
thickness. Furthermore, the measuring coil is fixed to the outside of the cell.
Consequently, each sample experiences the same surroundings, which results
in an equal homogeneity of the magnetic field for all samples. In practice this
means that the magnetic homogeneity after initial adjustment does not need to
be changed or at most by minor adjustment of the Z and Z2 shims. These mi-
nor adjustments can be done during the dummy scans (scans without data ac-
quisition, needed to acquire a steady state).
Water Suppression
Water suppression in automation is not trivial. Success is dependent on shim-
ming and stable temperature. The advantage of screening with flow-injection
NMR is, as mentioned earlier, that samples are very similar and that the envi-
ronment inside the probe is more or less constant. In practice this means that
initial shimming and determining the correct offset is sufficient to reach a good
level of water suppression. Software manipulation of the data can cosmetically
improve the spectrum, so that automated processing is possible. If resonances
of interest are (too) close to the water resonance, increasing or decreasing the
sample temperature will shift the residual water resonance to a more favorable
position.
Sensitivity and Detection Limit
The detection limit on a Bruker 500 MHz machine is in the higher micromolar
range. By taking more scans this can be lowered, but then the throughput rap-
idly decreases. When screening for new biocatalysts, substrate concentrations
are used that mimic industrial application conditions whenever possible, which
corresponds to concentrations of more than 50 mM. That means that in the
case of a conversion of 1%, 0.5 mM should be detectable, which in practice is
possible. Only when the resonances of the product are highly overlapped by
those of background compounds, conditions should be optimized (pH, tempera-
ture) to allow detection.
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Back Mixing
An essential prerequisite for applying flow-injection NMR in general is that sam-
ples do not mix in the flow-cell. Separation of samples is accomplished by adding
cleaning segments and small gaps with air to the sample train that is injected. The
amount of back mixing is influenced by factors such as aspiration and dispensing
speed, amount of cleaning liquid, number and size of trails, and composition of
sample. Some samples can be very sticky, such as solutions containing sugars
and polyols. Trial and error with different conditions will allow optimization of
the method to be used. When screening large libraries (e.g. 10000 samples or
more) for a specific enzymatic activity, speed is limiting. Two factors balance
the overall speed possible: sample preparation and data acquisition. The total ac-
quisition time should be equal to the time needed for the preparation of the next
sample. This time plus the time that is needed for the actual dispensing of the
sample then determines the repetition time. In the case of sufficient sensitivity,
sample preparation and sample dispensing become limiting. However, only a
few positive hits at most are to be expected and mixing becomes less critical
and some mixing can be tolerated. Even 10% of mixing is acceptable, because
samples will then report 10% of the activity of the previous sample following a
hit and can therefore easily be recognized. An automatic routine in a spreadsheet
program can also correct for carryover from the previous experiment.
Samples can be recovered, but this limits the speed to an unacceptable low
level for screening purposes.
Automation (Data Acquisition)
To handle a large number of samples, the NMR manufacturers provide standard
software so that the operation of a flow probe does not differ from that of a clas-
sical sample changer [45].
Automation (Data Processing and Handling)
To keep track of the fast acquisition of NMR data, further processing of the data
(Fourier transformation, phase correction, baseline correction and integration)
needs to be completely automated. Modern NMR software supplies commands
that can do automatic phase- and baseline correction that can also be implemented
in macros. One method is to run such a macro each time a measurement has fin-
ished, the other, more reliable way is to determine the correct phase settings for
the first experiment of a series (for instance a microtiter plate) and to run the pro-
cessing for the series with these settings after the measurement of a microtiter
plate has been finished. Automatic baseline correction is easiest when, after initial
baseline correction of the complete spectrum, selected regions of interest are cor-
rected with optimized parameters for a specific type of region. Integrals can be set
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automatically once they have been determined for a single experiment. In practice
the settings are constant for all similar experiments.
To calculate conversions, integrals are put into a text file, which can then be im-
ported into a spreadsheet on a separate computer. There, calculations can be per-
formed by macros that can easily be adapted for individual experiments. For eval-
uation purposes, a graphical representation of the conversion in a microtiter plate
(see Figure 4.20) and a list sorted on highest conversion can be added to a report.
Cleaning
As crude enzyme preparations contain some residual biomass even after centrifu-
gation, precautions have to be taken to prevent microbial growth in the flow system.
Adding sodium azide to the cleaning and pushing liquids and flushing the last
sample with one or more dummy samples with cleaning liquid is sufficient for
routine operation. Regular cleaning with surfactant solution, alcohol, ammonia,
and diluted nitric acid is done to remove traces of biomass and sticky components.
Capacity
NMR machines can run more or less unattended for weeks, as long as the regu-
lar filling intervals for liquid nitrogen and helium are maintained. The Gilson
215 liquid handler can contain 10 microtiter plates and most of the screenings
are done in 96-well format. With a repetition time of 1 min, new samples have
to be added every 16 h, which during the weekends has to be carried out four
times when large screenings are done. Switching to a 384-well format, com-
posed of four 96-well plates, limits this number to one at most. Deep-well plates
of this format can contain 360 L liquid, which is sufficient for operation with a
4 mm flow-cell. The use of a 3 mm cryo flow-cell can be done with 160 L and
can thus limit the amount of sample needed.
4.4.1.4 Example: Screening of a Bacterial Expression Library
for Amidase-containing Clones
As well as -H--amino acids, ,-disubstituted -amino acids are also a group of
industrial relevance, as is exemplified by the use of l--methyl-3,4-dihydroxyphe-
nylalanine (l--methyldopa, 19) as an antihypertensive drug [48, 49] and -methyl-
valine (18a, Figure 4.15) as an intermediate for the herbicide Arsenal (20), cur-
rently marketed as its isopropylamine salt by BASF, and related herbicides [50].
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These disubstituted amino acids can be produced in enantiomerically pure
form by an amidase process that is quite similar to the process for the produc-
tion of -H--amino acids [30]. In this case, however, ketones are used as start-
ing material instead of aldehydes and, since the l-aminopeptidase from P. puti-
da ATCC 12633 is not active for this class of amides, a different amidase is ap-
plied in the resolution step [30].
The screening assay presented here was intended to identify new amidases
with activity towards ,-disubstituted -amino acid amides. For this purpose, -
methyl leucine amide (17b) was used as substrate, which will be converted into
-methyl leucine (18b) by positive clones (Figure 4.15). The actual gene library
screening was performed as follows.
Procedure 4.5: Amidase Screening by NMR
96-Well microtiter plates filled with rich medium (200 L per well) supple-
mented with the appropriate antibiotic, were inoculated with transformants
from a bacterial gene library in E. coli. After incubation for 48 h at 22 C at
a shaking speed of 600 rpm, 100 L of culture was transferred from each
well to a wide well plate containing 300 L dl--methyl leucine amide
(67.5 mM, pH 8.0) and incubated for 24 h at 40 C. Subsequently, the micro-
titer plates were centrifuged for 10 min at 1000g to pellet the cells. From
the supernatant in each well, 300 L was transferred to deep-well 96-well
microtiter plates each containing 50 L D2O with 40 g L
–1 maleic acid,
20 g L–1 EDTA, and 1 g L–1 DSS (2,2-dimethyl-2-silapentane-5-sulfonate so-
dium salt) (pH of this solution was adjusted to 6.5). 1H-NMR measure-
ments were performed at 500 MHz on a Bruker Avance spectrometer using
a 4 mm flow-cell (active volume 120 L) equipped with standard Bruker
software (XWINNMR version 3.1 and ICONNMR 2.6). Aspiration and dis-
pensing speed were set to 8 mL min–1 and the sample volume was 300 L.
The total measurement time was 25 s (eight scans with two dummy scans),
equalling the simultaneous preparation time of the next sample. The overall
repetition time was about 60 s. Processing (Fourier transformation, phase
correction, baseline correction, and integration) was done per microtiter
plate, using parameters optimized for the first sample of the microtiter
plate. After a quick visual check of the spectra, the integral values were ex-
ported to a text file, which was imported into an Excel file, designed to cal-
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culate the conversions. For each microtiter plate, conversion figures and
graphical representation of the results were displayed and plotted.
In total 120 microtiter plates (11520 samples) were screened in this way,
which led to the identification of two positive clones (see also Section
4.4.2.1). A spectrum of one of these positive clones is given in Figure 4.17.
4.4.1.5 Example: Identification of a Phenylpyruvate Decarboxylase Clone
Phenylpyruvate decarboxylases catalyze the decarboxylation of phenylpyruvate
(21) resulting in the formation of phenylacetaldehyde (22) (Figure 4.18).
Interestingly, this enzyme can also catalyze the asymmetric acyloin condensa-
tion of phenylpyruvate with various aldehydes [51, 52]. In a similar set-up as
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Fig. 4.17 1H-NMR spectrum of a positive hit in the screening for an
amidase that hydrolyzes DL--methyl leucine amide.
Fig. 4.18 Natural reaction catalyzed by the enzyme phenylpyruvate decarboxylase.
that used in the amidase screening described in Section 4.4.1.4, but with
120 mM phenylpyruvate as substrate, a bacterial gene library in E. coli was
screened and assayed with flow-injection NMR to isolate the phenylpyruvate
decarboxylase gene from this microorganism. On visual inspection of the spec-
tra it turned out that there were no hits, as formation of phenylacetaldehyde
could be demonstrated in none of the wells. However, a few spectra could be
found where the oxidation product of this compound (phenylacetic acid, 23)
was detected (Figure 4.19). Apparently, the primary aldehyde product had been
oxidized into the carboxylic acid. Further examination of these clones by nucleo-
tide sequence determination followed by subcloning proved that these hits did
indeed contain the desired phenylpyruvate decarboxylase gene.
4.4.1.6 Example: Identification of Amidase Mutants with Improved Activity
towards -Methylphenylglycine Amide
Using a combination of different directed evolution techniques such as epPCR
and saturated mutation primer PCR DNA shuffling [53], the specific activity of
the l-amidase from Ochrobactrum anthropi NCIMB 40321 towards dl--methyl-
phenylglycine amide (17c, Figure 4.15) could be improved by approximately
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Fig. 4.19 Spectrum of a positive hit in the phenylpyruvate decarboxylase
screening. This spectrum indicates the formation of phenylacetic acid
(resonance indicated by the arrow) rather than phenylacetaldehyde, most
likely because of (chemical) oxidation of the screening product formed.
500%. Also in this case the screening method used was identical to that in exam-
ple 4.4.1.4, now using dl--methylphenylglycine amide as substrate. In Figure
4.20 a graphical representation of the results of a typical microtiter plate is given.
4.4.2
Fast LC/MS for High-throughput Screening of Enzymatic Activity
Among the techniques developed for high-throughput screening, mass spec-
trometry offers good potential to act as a generic screening method and has
gained increased attention in the past decade [54, 55]. Some high-throughput
MS screening methods for biocatalysts have been described, without combina-
tion with chromatography. For example MALDI MS methods have been devel-
oped and optimized to quantify low-molecular-mass substrates and products of
enzyme-catalyzed reactions [56, 57]. Methods based on electrospray ionization
mass spectrometry (ESI MS) have been developed for the determination of con-
version [58] and enantioselectivity [59, 60] of biocatalytic reactions, in which
103–104 biocatalysts can be screened per day. Despite the high throughput that
can be realized by the above-mentioned flow-injection analysis (FIA) MS sys-
tems, by-products may not be detected in this mode [61] and screening for
4 Industrial Perspectives on Assays126
Fig. 4.20 Graphical representation of the results of one microtiter plate
obtained in the screening for an amidase with improved activity towards
-methylphenylglycine amide (expressed as % conversion).
enantioselective (bio)catalysts necessitates the use (and consequently the synthe-
sis) of pseudo-enantiomers (chiral compounds differing in absolute configuration
and isotopic labeling only) or pseudo-prochiral compounds [59]. The develop-
ment of simple, reliable LC/MS interfaces, most notably ESI and atmospheric
pressure chemical ionization (APCI), has spurred the development and accep-
tance of LC/MS methods, such that, nowadays, there are many laboratories that
routinely use LC/MS as the primary analytical method.
The LC system is used to fractionate a preparation and the mass spectrometer
is positioned as a detector, monitoring the effluent. With regard to fast LC/MS
methods for the analysis of small molecules (mol wt <1000) in biological ma-
trices, an overview of these methods has recently been published [62]. In this re-
view article, fast LC/MS methods for analytes in, for example, blood, plasma, se-
rum, urine, and saliva, are described. Both gradient and isocratic methods are
discussed, whereby ‘fast’ is defined as exhibiting a cycle time of less than
5 min. For the determination of enantioselectivity, fast chiral HPLC/MS meth-
ods are reported using commercial chiral stationary phases (CSP) [63–65]. De-
spite the fact that numerous LC/MS applications for blood and plasma are de-
scribed in the literature, relatively few studies deal with LC/MS applications for
medium to high-throughput screening of biocatalysts [66, 67].
Because of its sensitivity, specificity, and medium to high throughput capabil-
ity, LC/MS is often the method of choice for screening unpurified biotransfor-
mations where low conversion numbers are expected. The throughput required
with a large “random” screening population dictates for both the HPLC and
mass spectrometer a specific set-up. Fast chromatographic run times per sample
are required, which necessitate the use of short column lengths, accompanied
by sufficient efficiency. The latter may be realized by using either particulate
column packings with small particles (for instance 2 or 3 m) or silica rods.
With respect to the mass spectrometric part, both LC/MS and LC/MS/MS can
be run in both positive and negative ion modes.
4.4.2.1 Example: Screening of a Bacterial Expression Library
for Amidase-containing Clones [68]
This LC/MS biocatalyst screening was set up in our laboratory for validation of the
hits found with the flow-injection NMR screening assay described in Section
4.4.1.4. The screening assay was intended to determine amidase activity towards
-methyl leucine amide (17b, Figure 4.15) as example for ,-disubstituted -amino
acid amides, so the product of this reaction was -methyl leucine (18b, Figure 4.15).
Procedure 4.6: LC/MS Assay of Amidase Activity
The two 96-well plates out of 120 containing hits according to the flow-in-
jection NMR screening assay, were centrifuged for 10 min at 1000 g. From
the supernatant (cleared reaction mixture) in each well, 5 L was trans-
4.4 CCM Compliant Screening Methods Based on Generic Instrumental Assays 127
ferred to shallow 96-well microtiter plates each containing 245 L acetoni-
trile/water (50/50) supplemented with NH4OH (0.5 weight %, pH 10.8).
The LC/MS system used for the screening of the two plates consisted of an
Agilent 1100 system with a binary pump, a well-plate sampler with hand-
held controller and an Agilent 1100 mass-selective detector (MSD). For
HPLC, a 504.6 mm SpeedRod column (Merck) was used in combination
with an isocratic mobile phase (1.5 weight % acetonitrile in 0.1% formic
acid at a flow-rate of 4 mL min–1 at room temperature). This system oper-
ates well with 0.3–1 L injections and a whole-plate injection program.
Analysis time per well is 20 s, resulting in a cycle time of 32 min for a
96-well plate. The mass spectrometer was operated in the selected ion mode
(SIM) at m/z 146, that is the [M+H]+ ion of the acid, and at m/z 145, that
is the [M+H]+ ion of the acid amide.
To ensure quantitative LC/MS analysis, use of a complementary calibration
procedure as described in Section 4.3.2.1 is essential. The complementary ca-
libration mixtures were prepared by mixing a solution of dl--methyl leucine
amide HCl (67.5 mM) and a solution of l--methyl leucine and NH4OH
(67.5 mM each) in increasing ratios covering a range of 0–2.54 mM l--methyl
leucine (corresponding to 0–3.75% conversion of the l--methyl leucine
amide substrate). The starting concentration of the amino acid amide in
the 0% conversion calibration sample corresponds to the amount of amino
acid amide used as substrate in the screening experiments. A conversion of
50% means that all of the l-amino acid amide is converted into l-amino acid
and ammonia. As solvent for both solutions, the same rich medium as ap-
plied in the screening protocol was used in which E. coli had been cultured
over 24 h at 20 C. After removing the cells by centrifugation, the supernatant
was diluted 4 times with Milli-Q water (Millipore, Bedford, MA, USA) before
dissolving the calibration curve components. The chromatograms obtained
for the calibration solutions by SIM are given in Figure 4.21.
In all calibrations carried out during the LC/MS screening assay, linear re-
gression analysis indicated that the correlation coefficient of each single cali-
bration curve was better than 0.994. The coefficient of variation for seven ca-
librations was of the order of 5%. The detection limit of conversion that could
be determined was about 0.1% conversion in the case of -methyl leucine
amide. For quantitation, the ratio of the acid and the amide (positive ion de-
tection) was taken. By this method of internal standardization, the effect of
possible evaporation is corrected. The two hits identified by flow-injection
NMR were also found by LC/MS assay. The results are shown in Table 4.2.
The percentage conversion found by using LC/MS was somewhat lower than
those measured by flow-injection NMR, however, in both assays the two pos-
itive hits could be clearly identified among the whole sample population.
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4.4.2.2 Example: Screening of Enzymatic Racemase Activity [66]
As a second example we describe the use of LC/MS for the screening of enzy-
matic racemase activity. In this specific case, clones from an expression library
were screened for a racemase for -amino--caprolactam (ACL, 24) using a fast
chiral LC separation method combined with ion-spray MS as the detection tech-
nique. The determination of the conversion in a racemase reaction necessitates
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Fig. 4.21 Chromatograms of complementary calibration mixtures
recorded in SIM mode (m/z 145 is [M+H]+ of -methyl leucine amide
(black line); m/z 146 is [M+H]+ of -methyl leucine (dashed line)).
The abundance plots are normalized to full scale.
Table 4.2 Amidase hit identification (expressed as % conversion of
DL--methyl leucine amide) in a bacterial gene library by flow-injection
analysis NMR (FIA NMR) and LC/MS.
Plate number Well number FIA NMR (% conv.) LC/MS (% conv.)
77 E4 3.7 3.3
97 B5 3.4 2.2
Fig. 4.22 Reaction catalyzed by an -amino--caprolactam (ACL) racemase.
the use of a method to distinguish both enantiomers of the substance, as one
enantiomer serves as substrate for the enzyme, while the other is the product of
the reaction (Figure 4.22).
Procedure 4.7: LC/MS Assay for Racemase
Using a Crownpak CR (+) column and an aqueous perchloric acid solution
as mobile phase, baseline separation of the ACL (24) enantiomers was ob-
tained. Since perchloric acid is a nonvolatile acid, this type of mobile phase
is not suited for interfacing with a mass spectrometer.
To circumvent this problem, the mineral acid may be substituted by a
short-chain organic acid as mobile phase additive. In the literature, the use
of trifluoroacetic acid and acetic acid as mobile phases for Crownpak col-
umns has been reported. In our case it is necessary to protonate the ACL
enantiomers in order to obtain sufficient retention and resolution on the
crownether stationary phase. As the pKa of ACL is 7.8, an acidic pH is nec-
essary to transform the enantiomers into their ammonium form. A 0.1%
aqueous solution of formic acid (measured pH 2.6) was chosen as eluent
instead of the nonvolatile perchloric acid solution. The enantioselectivity
and resolution found by using the formic acid eluent were comparable
with those of the perchloric acid mobile phase. By setting the flow-rate to
1.5 mL min–1, a run time of 1 min per sample was obtained. Using overlap-
ping injections, a total analysis time of 56 min per 96-well microtiter plate
could be achieved. With respect to the LC/MS interface, the suitability of
both the turbo ion spray and the heated nebulizer interface for the ioniza-
tion of ACL were evaluated. It turned out that the sensitivity for ACL was
of the same order of magnitude for both interfaces. However, in the heated
nebulizer interface severe peak broadening occurred, which resulted in
overlapping peaks of the enantiomers at a flow-rate of 1.5 mL min–1. As
peak broadening in the heated nebulizer interface is flow-dependent, flow
splitting was tried. At lower flow rates the peak broadening improved, but
sensitivity was lost as this type of interface is a mass-sensitive interface.
It was noticed that peak broadening in the turbo ion-spray interface was
minimal and that the peak separation obtained by LC/UV could be main-
tained in this MS interface. Ion-spray MS in the positive ion mode was
therefore chosen as detection technique for measurement of the [M+H]+
ion of the ACL enantiomers at m/z 129. The d-ACL enantiomer showed
hardly any retention on the column and coeluted with components arising
from the biological matrix. This coelution caused some ionization suppres-
sion of the signal of the d-ACL enantiomer. The m/z 129 signal showed no
contribution from the biological matrix. Figure 4.23 shows selected ion
chromatograms of racemic ACL with and without a biological matrix.
The signal for the d-enantiomer was suppressed by about 20%. On the
other hand, the l-enantiomer was hardly influenced by the biological ma-
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trix. As the goal of the assay was the measurement of the product of the ra-
cemase reaction, that is the d-ACL enantiomer, the difference in suppres-
sion between the two enantiomers was not a problem. In the preparation of
the calibration standards, a racemase reaction was mimicked in a biological
matrix that was comparable with the matrix of the expression library sam-
ples. The concentration of the calibration samples covered the range of 0–
50% conversion of l-ACL, with 50% conversion implying the presence of
equal amounts of d-ACL and l-ACL. Figure 4.24 shows a typical intra-day
calibration graph, which was measured in quadruplicate every day.
The nonlinearity of the calibration curve is caused by the limited dynamic
range of ion-spray ionization. Ionization suppression and ion signal satura-
tion account for this effect [69]. For the calibrated concentration range, the
intra-day coefficient of variation (four replicate injections of the calibration
samples) was typically around 8%. The inter-day coefficient of variation was
about 15%. The sensitivity of the method allowed a theoretical detection
limit of 0.1% conversion. In practice this level could not be attained as the
substrate of the reaction already contained 0.5% d-ACL. Because of this im-
purity of the substrate, the detection limit for the actual screening was set
to 1% conversion.
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Fig. 4.23 Selected ion chromatograms
(m/z 129) showing the influence of the
biological matrix on the signal intensity
of the both ACL enantiomers. Chroma-
togram (black line) showing the analy-
sis of a racemic mixture of ACL without
biological matrix and chromatogram
(dashed line) with biological matrix.
(Reprinted from Journal of Chromatography
A, Vol. 1020, H. J.W. Henderickx, A.L.L.
Duchateau, P.C. Raemakers-Franken, Chiral
liquid chromatography-mass spectrometry
for high-throughput screening of enzymatic
racemase activity, pp. 69–74, Copyright
(2003), with permission from Elsevier).
In total almost 12000 clones from an expression library were analyzed on
a single Crownpak column. No significant change in column performance
was noticed after screening the total expression library.
4.5
Conclusions
Although timelines in chemical custom manufacturing are extremely short, the
two approaches outlined in this chapter will enable on-time identification of
new or improved biocatalysts. The first approach requires proactive development
of assay methods that are normally not suitable for this demanding business
field because of their long development time. This situation is typical for reader
assays requiring set-up of chemical derivatization or enzymatic cascade reac-
tions. Such chemical or enzymatic follow-up reactions are needed, as it is essen-
tial to assay the truly desired industrial conversion instead of using artificial col-
orimetric or fluorometric substrates. The second approach is based on use of in-
strumental assay techniques such as NMR and MS. As these kind of techniques
are very broadly applicable (“generic”), leading to rather short development
times, the CCM timelines can be met without any proactive development. We
are convinced that by these two screening approaches one of the major hurdles
for further implementation of biocatalysis in CCM, in many cases offering the
cheapest and most environmentally benign solution, can be cleared.
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Fig. 4.24 Typical intra-day calibration
graph for D-ACL, showing four replicate
data points per calibration level. Opti-
mal fit is obtained with a quadratic
curve y=–0.0106x2 +2.9546x +2.3098.
The coefficient of regression is 0.9992.
(Reprinted from Journal of Chromatography
A, Vol. 1020, H. J.W. Henderickx, A.L. L.
Duchateau, P.C. Raemakers-Franken, Chiral
liquid chromatography-mass spectrometry
for high-throughput screening of enzymatic
racemase activity, pp. 69–74, Copyright
(2003), with permission from Elsevier).
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